Sai Life Sciences Limited has announced its earnings conference call for the third quarter of FY26, scheduled for February 6, 2026, from 4:00 PM to 5:00 PM IST. The pharmaceutical contract research and manufacturing organization will discuss its unaudited financial results for the third quarter and nine months ended December 31, 2025. The session will include a management discussion followed by an interactive Question & Answer session with analysts and institutional investors.
The conference call will feature key senior management representatives leading the quarterly performance discussion. Krishna Kanumuri, Managing Director & Chief Executive Officer, and Siva Chittor, Director and Chief Financial Officer, will participate in the earnings call. The format will begin with a brief management discussion on earnings performance, followed by the Q&A session with participants.
Participants can join through multiple channels with domestic dial-in numbers +91 22 6280 1107 and +91 22 7115 8008 provided for Indian participants. International attendees have access to toll-free numbers including USA (18667462133), UK (08081011573), Singapore (8001012045), and Hong Kong (800964448). The company has also arranged a pre-registration facility for participants who wish to dial in directly without waiting for operator assistance.
The announcement was made on January 28, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Runa Karan signed the regulatory filing, ensuring proper disclosure to both BSE Limited (Scrip Code: 544306) and National Stock Exchange of India Limited (Scrip Symbol: SAILIFE). Sai Life Sciences operates as a global Contract Research, Development, and Manufacturing Organization (CRDMO), headquartered in Hyderabad.
